 HOUSTON, Dec. 10, 2020 GLOBE NEWSWIRE -- Bellicum Pharmaceuticals, Inc. NASDAQ:BLCM, a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and apheresis of the first patient in the Phase 12 clinical trial for BPX-603 in patients with tumors that express human epidermal growth factor 2 HER2. BPX-603 is Bellicums first dual switch GoCAR-T product candidate that incorporates the companys iMC activation and CaspaCIDe safety switch technologies. 